Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study

Abstract

Background: Preliminary studies have shown that rituximab (RTX) is effective in the treatment of active Graves' orbitopathy (GO).

Methods: We conducted a double-blind, randomized trial (European Clinical Trials Database [EudraCT] 2007-003910-33) to compare RTX with iv methylprednisolone (ivMP) in patients with active moderate to severe GO. Thirty-two patients were randomized to receive either ivMP (7.5 g) or RTX (2000 or 500 mg). The primary end point was the decrease of the clinical activity score of 2 points or to less than 3 at week 24. Changes of proptosis, lid fissure, diplopia and eye muscle motility, and quality of life score were secondary end points. The number of therapeutic responses, disease reactivation, and surgical procedures required during follow-up and the patients' quality of life were also assessed.

Results: The clinical activity score decreased with both treatments but more after RTX at 16, 20, and 24 weeks (P < .04, P < .02, P < .006, respectively), whether 1000 mg RTX twice or 500 mg RTX once was used (P = NS). At 24 weeks 100% of RTX patients improved compared with 69% after ivMP (P < .001). Disease reactivation was never observed in RTX patients but was observed in five after ivMP. Patients treated with RTX scored better motility at 52 weeks in both the right (P = .014) and the left eye (P = .026). Overall rehabilitative surgical procedures carried out during follow-up (at 76 wk) were 12 in 16 ivMP patients and 5 in 15 RTX patients (P = .049).

Conclusions: The results of this trial confirm preliminary reports on a better therapeutic outcome of RTX in active moderate to severe GO, when compared with ivMP, even after a lower RTX dose. The better eye motility outcome, visual functioning of the quality of life assessment, and the reduced number of surgical procedures in patients after RTX seem to suggest a disease-modifying effect of the drug.

Figures

Figure 1.

Randomized controlled trial of RTX vs ivMP for the treatment of active moderate to severe GO (EUDRACT 2007–003910–33): study design and schedule of infusion with clinical, biochemical, and immunological assessment and follow-up up to 76 weeks from baseline.

Figure 2.

Motility assessment in patients with GO after treatment with either ivMP or RTX. A, Calculation of the TMS by assessment of the degrees of ductions by the Foerster-Goldman perimeter. B, Outcome of TMS at 24 and 52 weeks after ivMP and RTX in both the right (OD) and the left (OS) eye (Wilcoxon).

Figure 3.

Analysis of the primary end point of the study. A, Changes of the CAS in patients treated with either ivMP or RTX from baseline up to 24 weeks of follow-up (Wilcoxon). B, Outcome of the primary end point of the study after ivMP and RTX at 12 and 24 weeks (Fisher exact test). C, Changes of the CAS after a high dose (2000 mg) of low-dose (500 mg) RTX from baseline up to 24 weeks of follow-up (Mann-Whitney).

Figure 4.

Changes of serum TRAbs in patients with active GO after either ivMP or RTX from baseline up to 76 weeks of follow-up. *, P < .05 (Wilcoxon).